4.8 Article

BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1 alpha activation

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1807112115

关键词

BRCA1-IRIS; metastasis; HIF-1 alpha; PTEN

资金

  1. National Cancer Institute (NCI) Cancer Center Support Grant NIH [5P30CA06516]
  2. NCI [2P01CA080111]
  3. DFCI/Novartis Program in Drug Discovery
  4. Breast Cancer Research Foundation
  5. Susan G. Komen Foundation for the Cure
  6. BRCA Foundation
  7. NATIONAL CANCER INSTITUTE [R35CA210057, R35CA210068, P50CA101942, P30CA006516, P01CA080111] Funding Source: NIH RePORTER

向作者/读者索取更多资源

BRCA1 is an established breast and ovarian tumor suppressor gene that encodes multiple protein products whose individual contributions to human cancer suppression are poorly understood. BRCA1-IRIS (also known as IRIS), an alternatively spliced BRCA1 product and a chromatin-bound replication and transcription regulator, is overexpressed in various primary human cancers, including breast cancer, lung cancer, acute myeloid leukemia, and certain other carcinomas. Its naturally occurring overexpression can promote the metastasis of patient-derived xenograft (PDX) cells and other human cancer cells in mouse models. The IRIS-driven metastatic mechanism results from IRIS-dependent suppression of phosphatase and tensin homolog (PTEN) transcription, which in turn perturbs the PI3K/AKT/GSK-3 beta pathway leading to prolyl hydroxylase-independent HIF-1 alpha stabilization and activation in a normoxic environment. Thus, despite the tumor-suppressing genetic origin of IRIS, its properties more closely resemble those of an oncoprotein that, when spontaneously overexpressed, can, paradoxically, drive human tumor progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据